JSC Grindeks opens the new Analytical Scaling Laboratory - first laboratory of this kind in the Baltic States

Today, 19th June Joint Stock Company Grindeks will unveil the new Analytical
Scaling Laboratory that is the only laboratory of this kind in the Baltic
States and one of the some in Eastern Europe. 

Laboratory project was developed within five years time; 3.2 million lats were
invested in the realisation of the project. Within the frameworks of the
project additional fundings from EU European Regional Development Fund
amounting 1.5 million lats. Resources attracted to the project are the largest
funding of ERDF allocated to singe Latvian company. 

In March of this year Grindeks new Analytical Scaling Laboratory was certified
accordingly to the requirements of Good Laboratory Practise that attests the
compliance of this laboratory with the highest laboratory standarts of the
world. 

„Realisation of this project strengthens positions of Grindeks as a
pharmaceutical business inovative products leader in the Baltic States.
Development of the laboratory will significantly increase competitiveness of
Grindeks in the European and USA markets- we will have the ability to develop,
as well as put into manufacturing new pharmaceutical product technologies and
attract foreign clients in a faster pace than our competitors,” tells Chairman
of the Board of JSC Grindeks Jānis Romanovskis. 

“Laboratory will secure stable growth of the sales of JSC Grindeks in the
developed Western pharmaceutical markets, as well as the quality of the
products respective to these high demanding markets. This will also be an
advantage for the Latvian scientists - an ability to order synthesis of the new
ingredients in this European class industrial laboratory,” emphasized Member of
the Board of JSC Grindeks, Director of the Active Pharmaceutical Ingredients
Business Unit Vitālijs Skrīvelis. 
 
Also Prime Minister of the Republic of Latvia Aigars Kalvītis and Minister of
Welfare of the Republic of Latvia Vinets Veldre will attend this event. 

JSC Grindeks is the leading pharmaceutical company in the Baltic States,
specializing in the manufacturing of heart and cardiovascular medications; CNS
drugs and anti-cancer agents. Its concern consists of four subsidiary companies
in Latvia, Estonia and Russia and seven representative offices. Production is
being exported to 40 countries. Main markets - Baltic States, Russia, and CIS
countries, Japan, Ireland, France, Netherlands and USA. Grindeks shares are
listed in the Official list of Riga Stock Exchange. 


Additional information:
Ilze Kreicmane
Deputy Manager of the Communications Department
JSC «Grindeks».
Phone.: 7083336
Ilze.kreicmane@grindeks.lv


 


Project is financed by the European Union European Regional Development Fund